Oxitoz 100mg/50ml Injection (Oxaliplatin Injection USP)

Oxitoz 100mg/50ml Injection contains oxaliplatin, a third-generation platinum cytotoxic chemotherapy medicine used mainly in colorectal cancer. It forms platinum-DNA adducts that interfere with DNA replication and transcription. Oxaliplatin 100mg/50ml injection is most familiar as part of FOLFOX (with infusional 5-FU/leucovorin) and CAPOX/XELOX (with capecitabine). Acute cold-triggered sensory symptoms and cumulative peripheral neuropathy are characteristic toxicities. The 100 mg/50 mL vial is a preparation strength, not a standard patient dose.

Oxaliplatin 100mg/50ml injection is approved in combination with fluoropyrimidine therapy for adjuvant treatment of stage III colon cancer after complete resection and for advanced/metastatic colorectal cancer. FOLFOX and CAPOX are also used in multiple gastrointestinal-cancer protocols according to current guidelines. Dose, duration, and choice of 3 versus 6 months in adjuvant colon cancer depend on recurrence risk, regimen, and neuropathy tolerance.

Oxaliplatin 100mg/50ml injection undergoes non-enzymatic conversion to reactive platinum complexes that form intra- and inter-strand DNA cross-links, blocking replication and transcription and triggering cell death.

MOSAIC: Adding oxaliplatin 100mg/50ml injection to 5-FU/leucovorin improved disease-free outcomes in resected stage III colon cancer and established FOLFOX as an adjuvant standard.
Metastatic CRC trials: Oxaliplatin-fluoropyrimidine combinations improved response and disease control in advanced colorectal cancer.

Just like any other medication, the Oxitoz 100mg/50ml Injection is also associated with some side effects. Most of the side effects are minor and usually go away within some time. Here are some of the symptoms, including:

Common side effects

• Cold-triggered tingling/dysesthesia
  
• Cumulative peripheral neuropathy
  
• Nausea/vomiting
  
• Diarrhea
  
• Fatigue
  
• Neutropenia/thrombocytopenia
  

Serious side effects

• Severe hypersensitivity/anaphylaxis
  
• Persistent sensory neuropathy
  
• Laryngopharyngeal dysesthesia
  
• Severe myelosuppression
  
• Hepatic sinusoidal injury
  
• QT prolongation/arrhythmia (rare)

Important: Dose and regimen must be prescribed by the treating specialist. Tablet/vial strength is not necessarily the patient dose. Do not start, stop, split, combine, or substitute treatment based on website information.

If an infusion is missed, contact the oncology unit. The cycle may be delayed or modified depending on blood counts and neuropathy. Do not compensate with an extra dose.

• CBC
  
• Neuropathy before each cycle
  
• Electrolytes and renal/liver function
  
• Infusion hypersensitivity
  
• Cumulative oxaliplatin exposure​
  

• Current oxaliplatin 100mg/50ml Injection prescribing information (Eloxatin/reference). https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022160s016lbl.pdf
  
• André T, et al. MOSAIC. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa032709
  
• Current NCCN colorectal-cancer guidelines. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1428
  
• National Library of medicine. Oxaliplatin 100mg/50ml Injection. https://www.ncbi.nlm.nih.gov/books/NBK557690/
  
• Annals of oncology. Oxaliplatin100mg/50ml Injection : A review of preclinicals and clinical trails. https://www.annalsofoncology.org/article/S0923-7534(19)48204-5/fulltext​